Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Immunovant's Chief Financial Officer, Eva Renee Barnett, sold a portion of her shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 2,189 shares of common stock at a weighted average price of $23.81 per share on January 15, 2025.
- She also sold 109 shares of common stock at a weighted average price of $24.19 per share on the same day.
- These sales were mandated by the company to cover tax withholding obligations related to the vesting of 5,479 restricted stock units (RSUs) that vested on January 12, 2025.
- The sales were not discretionary and were part of a 'sell to cover' transaction.
- Following these transactions, Ms. Barnett beneficially owns 324,766 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.
Risks
- The sale of shares by a company officer, even for tax purposes, could be perceived negatively by some investors.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.
Comparison to Industry Standards
- The 'sell to cover' method for handling tax obligations on vesting RSUs is a standard practice among publicly traded companies.
- Many companies use similar mechanisms to manage the tax implications of equity-based compensation for their executives.
- The price ranges at which the shares were sold are within normal market fluctuations for a company like Immunovant.
Stakeholder Impact
- The sale of shares by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 04/12/2023 | Date of grant of 87,664 restricted stock units (RSUs) to the holder. |
| 01/12/2025 | Date 5,479 of the granted RSUs vested. |
| 01/15/2025 | Date of the stock sales by the CFO to cover tax obligations. |
| 01/17/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Immunovant, IMVT, SEC Form 4, Eva Renee Barnett, Chief Financial Officer, stock sale, restricted stock units, RSU, tax withholding, sell to cover
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.